Drug Profile
Research programme: interleukin-8 antagonists - Sanofi-Aventis/Millennium
Latest Information Update: 04 Jun 2008
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals; sanofi-aventis
- Class Monoclonal antibodies; Small molecules
- Mechanism of Action Interleukin 8 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Reperfusion injury; Unspecified
Most Recent Events
- 14 May 2008 Millennium Pharmaceuticals has been acquired by Takeda
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 03 Feb 2004 No development reported - Preclinical for Reperfusion injury in USA (PO)